Amundi Asset Management US’s Neurogene NGNE Stock Holding History

Amundi Asset Management US’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-435	Closed	-$23K	–	1636
2018 Q2	$23K	Buy	+435	New	+$113K	﹤0.01%	1534

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Amundi Asset Management US's NGNE Position: Q3 2018 in Review

Amundi Asset Management US sold out of Neurogene (NGNE) in Q3 2018, closing a stake of 435 shares — an estimated $23K sold.

Amundi Asset Management US first reported a position in NGNE in Q2 2018 and held it in 1 quarter. The position peaked at $23K in Q2 2018. 45 funds tracked by Wall St. Rank hold NGNE as of Q3 2018.

Amundi Asset Management US reported no remaining Neurogene position as of Q3 2018 after selling out during the quarter.
Amundi Asset Management US sold 435 Neurogene shares in Q3 2018, an estimated $23K.
Amundi Asset Management US first reported a position in Neurogene in Q2 2018 and held it in 1 quarter.
Amundi Asset Management US's Neurogene position peaked at $23K in Q2 2018.
45 funds tracked by Wall St. Rank held Neurogene as of Q3 2018.

Based on Amundi Asset Management US's 13F filing for Q3 2018, filed 14 Nov 2018.